Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy

Journal of Clinical Immunology

Volumn 37, Issue 2, 2017, Pages 180-186

  Wasserman, Richard L ^a   Ito, Diane ^b   Xiong, Yan ^b   Ye, Xiaolan ^b   Bonnet, Patrick ^b   Li McLeod, Josephine ^b  

^a Allergy/Immunology Research Center of North Texas   (United States)

^b SHIRE   (United States)

Author keywords

Clinic; Home infusion; Hospital outpatient; Immunoglobulin G; Infection; Primary immunodeficiency

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PNEUMONIA; BRONCHITIS; CHILD; CONTINUOUS INFUSION; FEMALE; HEALTH CARE PLANNING; HOME CARE; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS PNEUMONIA; AMBULATORY CARE; COMPLICATION; INFANT; INFECTION; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; CHILD; CHILD, PRESCHOOL; FEMALE; HOME CARE SERVICES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INCIDENCE; INFANT; INFECTION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85011636456     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-017-0371-0     Document Type: Article

References (29)

1. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.
2. Gathmann B, Grimbacher B, Beauté J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;1:3–11.
3. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182–94.
4. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1–S63.
5. Ballow M. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ann Allergy Asthma Immunol. 2013;111(6 Suppl):S2–5.
6. Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol. 2011;31:924–6.
7. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354–60.
8. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–2.
9. Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388–95.
10. Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;3:323–31.
11. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.
12. Gammagard. GAMMAGARD LIQUID [immune globulin infusion (human) 10%] prescribing information 2014. In Baxter Healthcare Corporation (Westlake Village, CA).
13. Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol. 2013;33:49–54.
14. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130:951–7.
15. Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135:255–63.
16. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.
17. HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) solution for subcutaneous administration prescribing information. Baxter Healthcare Corporation; West Lake Village, CA. 2014. http://www.baxter.com/downloads/healthcare_professionals/products/HYQVIA_PI.pdf. Accessed 18 June 2015.
18. Luthra R, Quimbo R, Iyer R, et al. An analysis of intravenous immunoglobin site of care: home versus outpatient hospital. Am J Pharmacy Benefits. 2014;6:9.
19. Ballow M, Berger M, Bonilla FA, Buckley RH, Cunningham-Rundles CH, Fireman P, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang. 2003;84:202–10.
20. Souayah N, Hasan A, Khan HM, Yacoub HA, Jafri M, et al. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. J Clin Neuromuscul Dis. 2011;12(Suppl 4):S1–S10.
21. Menzin J, Sussman M, Munsell M, Zbrozek A. Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy. ClinicoEcon Outcomes Res. 2014;6:297–302.
22. Resnick ES, Bhatt P, Sidi P, Cunningham-Rundles C. Examining the use of ICD-9 diagnosis codes for primary immune deficiency diseases in New York State. J Clin Immunol. 2013;33:40–8.
23. SAS 9.3 Product Documentation. Available from: http://support.sas.com/documentation/93/. Accessed 18 June 2015.
24. Joo EH, Rha SY, Ahn JB, Kang HY. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer. 2011;19:971–8.
25. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.
26. Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH, Vivaglobin Study Group. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238–45.
27. Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621–9.
28. Mohamed AF, Kilambi V, Luo MP, Iyer RG, Li-McLeod JM. Patient and parent preferences for immunoglobulin treatments: a conjoint analysis. J Med Econ. 2012;15:1183–91.
29. cms.gov. Centers for Medicaid and Medicare Services. ICD-9 code lookup. http://www.cms.gov/medicare-coverage-database/staticpages/icd-9-code-lookup.aspx. Accessed 18 June 2015.